Stay updated on Phase I Study of MIK665 Mcl-1 Inhibitor in Lymphoma or Myeloma Clinical Trial
Sign up to get notified when there's something new on the Phase I Study of MIK665 Mcl-1 Inhibitor in Lymphoma or Myeloma Clinical Trial page.

Latest updates to the Phase I Study of MIK665 Mcl-1 Inhibitor in Lymphoma or Myeloma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedNew history entry 'Revision: v3.4.2' was added and an earlier 'Revision: v3.4.1' entry plus a site-wide funding notice were removed. These changes affect only the history metadata and do not modify study data or core page content.SummaryDifference0.7%

- Check20 days agoChange DetectedThe additions include a site-wide notice about government funding status and a new revision label (v3.4.1), and the previous revision (v3.4.0) was removed; these are metadata changes and do not affect the study's record content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check28 days agoChange DetectedChanges are UI/formatting updates (glossary display option, color-coded highlights for additions and deletions, and the revision label updated to v3.4.0); there is no impact on core study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check42 days agoChange DetectedThe record history shows a new Revision: v3.3.4 replacing the previous v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedA new revision entry (v3.3.3) was added to the record history, and the HHS Vulnerability Disclosure and a prior revision link were removed from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check91 days agoChange DetectedThe page history shows a new revision entry v3.3.2 and removes v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Phase I Study of MIK665 Mcl-1 Inhibitor in Lymphoma or Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase I Study of MIK665 Mcl-1 Inhibitor in Lymphoma or Myeloma Clinical Trial page.